Shares of Abattis Bioceuticals Corp (CNSX: ATT), engaged in cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America, recorded over 19.0% gain during each of the past two consecutive trading sessions with significant number of shares exchanging hands. ATT was the top performer in the Canadian healthcare sector after gaining 19.4% and closed at C$0.22 Tuesday, while recording significant trading volumes of 288,378 shares. During the past 5-trading sessions, ATT gained 26.5% with daily average trading volumes of 224,039 shares, while the stock fell by 24.6% during the past one month with daily average trading volumes of 231,562 shares. The stock is up 975.0% year-to-date.
Company Description:
Abattis Biologix Corporation (CNSX: ATT) researches, develops and manufactures natural botanical formulations to prevent or treat influenza strains in birds, humans and other mammals.
1-Year Stock Chart:
Source: Bloomberg
